清晨好,您是今天最早来到科研通的研友!由于当前在线用户较少,发布求助请尽量完整的填写文献信息,科研通机器人24小时在线,伴您科研之路漫漫前行!

Safety and efficacy of PD-1 and PD-L1 inhibitors in relapsed and refractory Hodgkin's lymphoma: a systematic review and meta-analysis of 20 prospective studies

医学 耐火材料(行星科学) 内科学 肿瘤科 淋巴瘤 荟萃分析 癌症研究 生物 天体生物学
作者
Chao Sun,Huixian Chen,Yongjing Wang,Chengyun Zheng
出处
期刊:Hematology [Informa]
卷期号:28 (1) 被引量:3
标识
DOI:10.1080/16078454.2023.2181749
摘要

Background: Inhibitors of programmed cell death protein 1 (PD-1) and programmed cell death ligand 1 (PD-L1) have been used in the treatment of relapsed and refractory Hodgkin's lymphoma (R/R HL) recently. To further understand the safety and efficacy of PD-1/PD-L1 inhibitors in R/R HL, we conducted this meta-analysis.Methods: Databases and the Clinical Registration Platforms have been systematically searched for related studies by March 2022. For safety analysis, the incidence and exhibition of any grade and grade 3 or higher adverse effects (AEs) were evaluated. Besides, severe AEs (SAEs), treatment-related deaths, and AEs leading to treatment discontinuation were summarized. The overall response rate (ORR), complete response (CR) rate, partial response (PR) rate, progression-free survival (PFS), overall survival (OS), and duration of response (DOR) were calculated for efficacy analysis. All processes were implemented mainly through the package Meta and MetaSurv of software R 4.1.2.Results: Overall 20 studies and 1440 patients were enrolled. The pooled incidence of any grade and grade 3 or higher AEs were 92% and 26%, respectively. The pooled ORR, CR rate and PR rate were 79%, 44% and 34%, respectively. The most common AEs were neuropathy (29%), nausea (27%), pyrexia (26%), and leukopenia (25%), and the most common grade 3 or higher AEs included leukopenia (10%), infusion reaction (8%), weight gain (3%), and neutropenia (2.7%). In survival analysis, pembrolizumab monotherapy appeared to perform better compared to nivolumab monotherapy.Conclusions: PD-1/PD-L1 inhibitors show promising efficacy and tolerable AEs in the treatment of R/R HL.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
大幅提高文件上传限制,最高150M (2024-4-1)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
淡淡醉波wuliao完成签到 ,获得积分10
24秒前
Fiona完成签到 ,获得积分10
29秒前
莫冰雪完成签到 ,获得积分10
29秒前
52秒前
1分钟前
陈秋完成签到,获得积分10
1分钟前
小王完成签到 ,获得积分10
1分钟前
rocky15应助jlwang采纳,获得10
1分钟前
LL完成签到 ,获得积分10
1分钟前
大荷子她爸完成签到 ,获得积分10
2分钟前
jjj完成签到 ,获得积分10
2分钟前
jiayoujijin完成签到 ,获得积分10
2分钟前
2分钟前
ybheart完成签到,获得积分10
2分钟前
天天快乐应助科研通管家采纳,获得10
2分钟前
青提芝士挞完成签到 ,获得积分10
2分钟前
Lucas应助btbu2015采纳,获得30
2分钟前
小鱼小鱼爱学习完成签到,获得积分10
2分钟前
197819782009完成签到 ,获得积分10
3分钟前
btbu2015发布了新的文献求助30
3分钟前
野性的柠檬完成签到,获得积分10
3分钟前
甜甜圈完成签到 ,获得积分10
4分钟前
4分钟前
白嫖论文完成签到 ,获得积分10
4分钟前
lovexa完成签到,获得积分10
4分钟前
Lenard Guma完成签到 ,获得积分10
4分钟前
风信子完成签到 ,获得积分10
4分钟前
呐殇完成签到,获得积分10
4分钟前
踏实的丹秋完成签到 ,获得积分10
5分钟前
酸奶球完成签到 ,获得积分10
5分钟前
明天就交稿完成签到 ,获得积分10
6分钟前
btbu2015发布了新的文献求助30
6分钟前
6分钟前
cheche发布了新的文献求助10
6分钟前
7分钟前
7分钟前
cheche完成签到,获得积分10
7分钟前
7分钟前
闪闪的谷梦完成签到 ,获得积分10
7分钟前
Singularity应助直率的无极采纳,获得20
7分钟前
高分求助中
Un calendrier babylonien des travaux, des signes et des mois: Séries iqqur îpuš 1036
Sustainable Land Management: Strategies to Cope with the Marginalisation of Agriculture 1000
Corrosion and Oxygen Control 600
Python Programming for Linguistics and Digital Humanities: Applications for Text-Focused Fields 500
Heterocyclic Stilbene and Bibenzyl Derivatives in Liverworts: Distribution, Structures, Total Synthesis and Biological Activity 500
重庆市新能源汽车产业大数据招商指南(两链两图两池两库两平台两清单两报告) 400
Division and square root. Digit-recurrence algorithms and implementations 400
热门求助领域 (近24小时)
化学 材料科学 医学 生物 有机化学 工程类 生物化学 纳米技术 物理 内科学 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 电极 光电子学 量子力学
热门帖子
关注 科研通微信公众号,转发送积分 2545875
求助须知:如何正确求助?哪些是违规求助? 2175672
关于积分的说明 5600226
捐赠科研通 1896383
什么是DOI,文献DOI怎么找? 946268
版权声明 565379
科研通“疑难数据库(出版商)”最低求助积分说明 503557